Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors

References

• Ferlay J, Bray F, Pisani P, et al. Globocan 2002: cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2002.
   Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241.
   PubMed Web of Science ®Google Scholar
• Zhao H, Jiang Y, Liu Y, et al. Endogenous estrogen metabolites as biomarkers for endometrial cancer via a novel method of liquid chromatography-mass spectrometry with hollow fiber liquid-phase microextraction. Horm Metab Res. 2015;47(2):158–164.
   PubMed Web of Science ®Google Scholar
• Farhat GN, Parimi N, Chlebowski RT, et al. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst. 2013;105(19):1496–1503.
   PubMedGoogle Scholar
• Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24(29):4783–4791.
   PubMed Web of Science ®Google Scholar
• Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293(23):1164–1167.
   PubMed Web of Science ®Google Scholar
• Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293(23):1167–1170.
   PubMed Web of Science ®Google Scholar
• Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976;294(23):1262–1267.
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G; C. Million Women Study. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543–1551.
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304–313.
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Lyytinen H, Pukkala E, et al. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol. 2009;114(6):1197–1204.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005;57(3):359–383.
   PubMed Web of Science ®Google Scholar
• Bilbao C, Ramírez R, Rodríguez G, et al. Double strand break repair components are frequent targets of microsatellite instability in endometrial cancer. Eur J Cancer. 2010;46(15):2821–2827.
   PubMed Web of Science ®Google Scholar
• Vassileva V, Millar A, Briollais L, et al. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res. 2002;62(14):4095–4099.
   PubMed Web of Science ®Google Scholar
• Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–1662.
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559–570.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–1802.
   PubMed Web of Science ®Google Scholar
• Forbes JF, Sestak I, Howell A, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387(10021):866–873.
   PubMed Web of Science ®Google Scholar
• Wiseman H. Tamoxifen: molecular basis of use in cancer treatment and prevention. 1st ed. Chichester: Wiley; 1994.
   Google Scholar
• Goldberg K, Bar-Joseph H, Grossman H, et al. Pigment epithelium-derived factor alleviates tamoxifen-induced endometrial hyperplasia. Mol Cancer Ther. 2015;14(12):2840–2849.
   PubMed Web of Science ®Google Scholar
• Cheng WF, Lin HH, Torng PL, et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66(2):233–237.
   PubMed Web of Science ®Google Scholar
• Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 2000;356(9233):881–887.
   PubMed Web of Science ®Google Scholar
• Williams-Brown MY, Salih SM, Xu X, et al. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol. 2011;126(3–5):78–86.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Troxel AB, Berlin JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008;26(25):4151–4159.
   PubMed Web of Science ®Google Scholar
• Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002;295(5564):2465–2468.
   PubMed Web of Science ®Google Scholar
• Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (review). Oncol Lett. 2015;9(4):1495–1501.
   PubMed Web of Science ®Google Scholar
• Taylor AH, Kalathy V, Habiba M. Estradiol and tamoxifen enhance invasion of endometrial stromal cells in a three-dimensional coculture model of adenomyosis. Fertil Steril. 2014;101(1):288–293.
   PubMed Web of Science ®Google Scholar
• Maia H Jr., Casoy J, Valente Filho J. Is aromatase expression in the endometrium the cause of endometriosis and related infertility? Gynecol Endocrinol. 2009;25(4):253–257.
   PubMed Web of Science ®Google Scholar
• Zhao P-L, Zhang Q-F, Yan L-Y, et al. Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases. Asian Pac J Cancer Prev. 2014;15(20):8975–8979.
   PubMedGoogle Scholar
• Usluogullari B, Duvan C, Usluogullari C. Use of aromatase inhibitors in practice of gynecology. J Ovarian Res. 2015;8:4.
   PubMed Web of Science ®Google Scholar
• Gao C, Wang Y, Tian W, et al. The therapeutic significance of aromatase inhibitors in endometrial carcinoma. Gynecol Oncol. 2014;134(1):190–195.
   PubMed Web of Science ®Google Scholar
• Markovitch O, Tepper R, Fishman A, et al. Long-term “protective” effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients. Breast Cancer Res Treat. 2009;113(2):321–326.
   PubMed Web of Science ®Google Scholar
• Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin. 2009;25(5):1105–1109.
   PubMed Web of Science ®Google Scholar
• Agorastos T, Vaitsi V, Pantazis K, et al. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):239–240.
   PubMed Web of Science ®Google Scholar
• Thangavelu A, Hewitt MJ, Quinton ND, et al. Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. Gynecol Oncol. 2013;131(3):613–618.
   PubMed Web of Science ®Google Scholar
• Lindemann K, Malander S, Christensen RD, et al. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer. 2014;14:68.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–936.
   PubMed Web of Science ®Google Scholar
• Bellone S, Shah HR, McKenney JK, et al. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol. 2008;199(3):e7–e10.
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–492.
   PubMed Web of Science ®Google Scholar
• Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat. 2007;105(Suppl 1):45–53.
   PubMed Web of Science ®Google Scholar
• El-Shamy M, Gibreel A, Refai E, et al. Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: a prospective cohort trial. Middle Fertil Soc J. 2012;17(2):111–115.
   Google Scholar
• van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321–331.
   PubMed Web of Science ®Google Scholar
• Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)–a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. Ann Oncol. 2010;21(3):498–505.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816.
   PubMed Web of Science ®Google Scholar
• Gray R, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31:suppl; abstr 5.
   Web of Science ®Google Scholar
• Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141.
   PubMed Web of Science ®Google Scholar
• Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12(12):1101–1108.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol. 2007;25(19):2664–2670.
   PubMed Web of Science ®Google Scholar
• Aihara T, Takatsuka Y, Ohsumi S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat. 2010;121(2):379–387.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–1271.
   PubMed Web of Science ®Google Scholar
• Margolese R, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387(10021):849–856.
   Google Scholar
• Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–1048.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–2391.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Schottinger JE, Shi J, et al. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015;121(13):2147–2155.
   PubMed Web of Science ®Google Scholar
• Chen J-Y, Kuo S-J, Liaw Y-P, et al. Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study. J Cancer. 2014;5(2):151–155.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21–29.
   PubMed Web of Science ®Google Scholar
• Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28(4):400–418.
   PubMed Web of Science ®Google Scholar
• Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–1273.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29(9):1117–1124.
   PubMed Web of Science ®Google Scholar
• Duffy S, Jackson TL, Lansdown M, et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod. 2006;21(2):545–553.
   PubMed Web of Science ®Google Scholar
• Duffy S, Jackson TL, Lansdown M, et al. The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol. J Obstet Gynaecol. 2010;30(6):596–604.
   PubMedGoogle Scholar
• Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633–643.
   PubMed Web of Science ®Google Scholar
• Aydiner A. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast. 2013;22(2):121–129.
   PubMed Web of Science ®Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–118.
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–446.
   PubMed Web of Science ®Google Scholar
• Shabani N, Mylonas I, Jeschke U, et al. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium. Anticancer Res. 2007;27(4A):2027–2033.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Stein M-P, Kumar NS, et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol. 2005;96(1):32–41.
   PubMed Web of Science ®Google Scholar
• Wilder JL, Shajahan S, Khattar NH, et al. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol. 2004;92(2):553–558.
   PubMed Web of Science ®Google Scholar